| Multifactorial approach to predicting resistance to anthracyclines C Desmedt, A Di Leo, E De Azambuja, D Larsimont, B Haibe-Kains, ... Journal of clinical oncology 29 (12), 1578-1586, 2011 | 216 | 2011 |
| Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer P Cottu, V D'Hondt, S Dureau, F Lerebours, I Desmoulins, PE Heudel, ... Annals of Oncology 29 (12), 2334-2340, 2018 | 157 | 2018 |
| Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a … FC Bidard, AC Hardy-Bessard, F Dalenc, T Bachelot, JY Pierga, ... The Lancet Oncology 23 (11), 1367-1377, 2022 | 152 | 2022 |
| Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors L Dal Lago, V D'Hondt, A Awada The Oncologist 13 (8), 845-858, 2008 | 149 | 2008 |
| Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial AM Oza, UA Matulonis, S Malander, S Hudgens, J Sehouli, ... The Lancet Oncology 19 (8), 1117-1125, 2018 | 131 | 2018 |
| Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer F Mazzeo, M Berlière, J Kerger, J Squifflet, L Duck, V D’Hondt, Y Humblet, ... Gynecologic oncology 90 (1), 163-169, 2003 | 124 | 2003 |
| Advanced ovarian cancer: phase III randomized study of sequential cisplatin–topotecan and carboplatin–paclitaxel vs carboplatin–paclitaxel P Hoskins, I Vergote, A Cervantes, D Tu, G Stuart, P Zola, A Poveda, ... JNCI: Journal of the National Cancer Institute 102 (20), 1547-1556, 2010 | 122 | 2010 |
| Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases W Jacot, E Pons, JS Frenel, S Guiu, C Levy, PE Heudel, T Bachelot, ... Breast cancer research and treatment 157, 307-318, 2016 | 121 | 2016 |
| Thrombopoietic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: a multicentric placebo-controlled, randomized phase Ib study V D'hondt, Y Humblet, TH Guillaume, S Baatout, C Chatelain, M Berliere, ... Blood 85 (9), 2347-2353, 1995 | 112 | 1995 |
| Current management of ovarian carcinosarcoma MS Mano, DD Rosa, E Azambuja, G Ismael, S Braga, V D'HONDT, ... International Journal of Gynecologic Cancer 17 (2), 2007 | 99 | 2007 |
| Dose-dependent interleukin-3 stimulation of thrombopoiesis and neutropoiesis in patients with small-cell lung carcinoma before and following chemotherapy: a placebo-controlled … V D'hondt, P Weynants, Y Humblet, T Guillaume, JL Canon, M Beauduin, ... Journal of clinical oncology 11 (11), 2063-2071, 1993 | 87 | 1993 |
| HER2-positive breast cancer: from trastuzumab to innovatory anti-HER2 strategies N Whenham, V D'Hondt, MJ Piccart Clinical breast cancer 8 (1), 38-49, 2008 | 68 | 2008 |
| Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial W Jacot, P Cottu, F Berger, C Dubot, L Venat-Bouvet, A Lortholary, ... Breast Cancer Research 21, 1-9, 2019 | 67 | 2019 |
| Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast … R Giuliani, V Durbecq, A Di Leo, M Paesmans, D Larsimont, JY Leroy, ... European journal of cancer 43 (4), 725-735, 2007 | 66 | 2007 |
| Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial A Oaknin, L Gladieff, J Martínez-García, G Villacampa, M Takekuma, ... The Lancet 403 (10421), 31-43, 2024 | 64 | 2024 |
| Novel treatment strategies for malignant melanoma: a new beginning? B Kasper, V D’Hondt, P Vereecken, A Awada Critical reviews in oncology/hematology 62 (1), 16-22, 2007 | 64 | 2007 |
| Phase III randomized study comparing 5 or 10 μg per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by … M André, E Baudoux, D Bron, JL Canon, V D'Hondt, MF Fassotte, ... Transfusion 43 (1), 50-57, 2003 | 64 | 2003 |
| Efficacy and safety of first-line single-agent carboplatin vs carboplatin plus paclitaxel for vulnerable older adult women with ovarian cancer: a GINECO/GCIG randomized … C Falandry, F Rousseau, MA Mouret-Reynier, F Tinquaut, D Lorusso, ... JAMA oncology 7 (6), 853-861, 2021 | 62 | 2021 |
| Prognostic impact of ESR1 mutations in ER+ HER2-MBC patients prior treated with first line AI and palbociclib: An exploratory analysis of the PADA-1 trial. FC Bidard, C Callens, F Dalenc, B Pistilli, T De La Motte Rouge, F Clatot, ... Journal of Clinical Oncology 38 (15_suppl), 1010-1010, 2020 | 57 | 2020 |
| Novel treatment strategies for soft tissue sarcoma B Kasper, T Gil, V D’Hondt, M Gebhart, A Awada Critical reviews in oncology/hematology 62 (1), 9-15, 2007 | 55 | 2007 |
